Paeds Vivas · cardiology
Cyanotic newborn and critical congenital heart disease screening — branching viva
Branching viva on the cyanotic newborn: interpreting the pulse-oximetry screen, starting prostaglandin E1 before the echocardiogram, separating cyanotic congenital heart disease from pulmonary and sepsis mimics, and escalating to a cardiac centre.
On this page & tools
Target exams
Opening question
A thirty-hour-old term infant is dusky on feeding but comfortable, with SpO₂ of 86 per cent in the right hand and 84 per cent in the foot in air and no murmur. Interpret the screen against the thresholds, and tell me your immediate next step and your immediate management. [2] [9]
Branch 1 — the well-looking blue baby
The baby looks well and the team wonders whether the saturation can be watched. Why does the appearance not lower your concern, which bedside findings localise a cardiac lesion, and why is the absence of a murmur a trap rather than a reassurance? [2]
Branch 2 — oxygen and the duct
The team asks whether to give 100 per cent oxygen while waiting. Explain the principle that governs oxygen in a suspected duct-dependent mixing lesion, name the drug that reopens the duct, its starting dose range, and why it must precede the echocardiogram. [9] [8]
Branch 3 — the differential and the hyperoxia test
The baby has a metabolic acidosis and a septic screen is sent. Discuss the differential diagnosis of neonatal cyanosis, the interpretation and the limits of the hyperoxia test, and the investigation that settles cardiac versus pulmonary disease. [2]
Branch 4 — the collapsed infant and the screening failure
Now picture the same lesion missed and the baby collapsing at home at forty-eight hours. Explain why this is a failure of the layered screening programme, and describe the three layers that should have detected the lesion and why each can miss. [1] [2]
Closing — the principle in one sentence
In one sentence, what is the prostaglandin-first principle of the cyanotic newborn, and why does the general paediatrician's speed to reopen the duct matter more than the speed of the diagnosis? [8] [1]
References
- [1]de-Wahl Granelli A, Wennergren M, Sandberg K, et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ, 2009.PMID 19131383
- [2]Mahle WT, Newburger JW, Matherne GP, et al. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation, 2009.PMID 19581492
- [9]Vari D, Xiao W, Behere S, et al. Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines? Cardiol Young, 2021.PMID 33140712
- [8]Aykanat A, Yavuz T, Özalkaya E, et al. Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease. Pediatr Cardiol, 2016.PMID 26260095